Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 5Recruiting 3Not yet recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Head & Neck 3

Conditions

Carcinoma, Hepatocellular 19Stomach Neoplasms 12Colorectal Neoplasms 10Rectal Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Esophageal Squamous Cell Carcinoma 5Pancreatic Neoplasms 4Esophageal Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Neoplasm Metastasis 3Nasopharyngeal Carcinoma 3Lung Neoplasms 3Triple Negative Breast Neoplasms 2Endometrial Neoplasms 2Turcot syndrome 1Thyroid Neoplasms 1Squamous Cell Non-small Cell Lung Cancer 1Spinocerebellar Degenerations 1Sarcoma 1Salivary Gland Malignant Neoplasms 1Resectable NSCLC 1Recurrence 1Rare Tumor 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neuroblastoma 1Neoplasms 1NSCLC 1Microsatellite Stable Metastatic Colorectal Cancer 1Metastatic Gastroesophageal Junction Adenocarcinoma 1

Interventions

Cisplatin 27Gemcitabine 22toripalimab 19Radiotherapy, Intensity-Modulated 18Capecitabine 10Radiotherapy 8Magnetic Resonance Spectroscopy 8nimotuzumab 7camrelizumab 7Specimen Handling 7Immune Checkpoint Inhibitors 7spartalizumab 5Drug Therapy 5Docetaxel 5Nivolumab 4Biopsy 4sintilimab 3Surgical Procedures, Operative 3Radiosurgery 3Platinum 3Fluorouracil 3Endoscopy 3Blood Specimen Collection 31,2-diaminocyclohexaneplatinum II citrate 3tislelizumab 2pembrolizumab 2irinotecan sucrosofate 2envafolimab 2apatinib 2anlotinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Nasopharyngeal Carcinoma × sintilimab × Clear all
NCT07581821 2026-05-12

Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 2 Recruiting
33 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT07459296 2026-03-16

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

First Affiliated Hospital of Guangxi Medical University

Phase 3 Recruiting
266 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT05707819 2023-02-01

Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

Cancer Hospital of Guangxi Medical University

Recruiting
43 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡